Foghorn Therapeutics Inc. — Form 8-K
Filed October 1, 2026 · analyzed by the 8-K Agent
8-K
▼ Likely negative
significance 72/100
What the filing says
Foghorn and Eli Lilly terminated the FHD-909 (SMARCA2 degrader) program on October 1, 2026, following Phase 1 data showing inadequate efficacy despite favorable safety. The Selective SMARCA2 degrader program is also discontinued. Foghorn will implement a 40% workforce reduction and reprioritize resources toward wholly owned programs (EP300 degrader, oral immunology/inflammation program, CBP degrader, induced proximity platform) to extend cash runway into H2 2029.
Why this rating
Loss of major partnership and lead program; 40% headcount cut; extends only to H2 2029. Meaningful relative to $172M market cap but company retains proprietary pipeline and near-term runway.
Price action (we called it negative)
at our read pending | +10 min pending | +30 min pending | +1 hr pending | +4 hrs pending |
Quotes via Yahoo Finance at capture time; for filings arriving outside market hours the clock starts at the next open. Not investment advice. How accurate are our calls? →
See more from October 1, 2026.
EDGAR·FLOW summarizes public SEC EDGAR filings with automated analysis. Materiality scores and stock-impact predictions are algorithmically generated and are not investment advice. Always verify against the source filing on SEC.gov.